KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) EPS (Weighted Average and Diluted) (2016 - 2026)

Eli Lilly filings provide 15 years of EPS (Weighted Average and Diluted) readings, the most recent being $8.26 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 169.93% to $8.26 in Q1 2026 year-over-year; TTM through Mar 2026 was $28.15, a 129.05% increase, with the full-year FY2025 number at $22.95, up 95.99% from a year prior.
  • EPS (Weighted Average and Diluted) hit $8.26 in Q1 2026 for Eli Lilly, up from $7.39 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $8.26 in Q1 2026 to a low of -$0.06 in Q3 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $2.42 (2023), compared with a mean of $3.27.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 103.73% in 2023 and later skyrocketed 1883.33% in 2024.
  • Eli Lilly's EPS (Weighted Average and Diluted) stood at $2.14 in 2022, then rose by 13.08% to $2.42 in 2023, then soared by 101.65% to $4.88 in 2024, then surged by 51.43% to $7.39 in 2025, then increased by 11.77% to $8.26 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $8.26 (Q1 2026), $7.39 (Q4 2025), and $6.21 (Q3 2025) per Business Quant data.